Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis

Core Insights - Telix Pharmaceuticals has initiated a Phase 3 clinical trial for Illuccix® and Gozellix® to expand their indications to include prostate cancer diagnosis [1][5] - The BiPASS™ study aims to evaluate the effectiveness of combining MRI and PSMA-PET imaging in diagnosing prostate cancer, potentially allowing some patients to avoid unnecessary biopsies [2][4] - The study plans to enroll 204 patients across Australia and the U.S. in a single-arm, multicenter, prospective, open-label trial [2][3] Company Overview - Telix Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals [8] - The company is headquartered in Melbourne, Australia, with operations in multiple countries including the U.S., U.K., and Japan [8] - Telix is listed on both the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX) [8] Clinical Study Details - The first patient in the BiPASS™ study was dosed at the Australian Prostate Centre, with imaging conducted at the Melbourne Theranostic Innovation Centre [3] - The study builds on previous research demonstrating the advantages of MRI and PSMA-PET imaging in prostate cancer diagnosis [6][7] - The potential market expansion for Telix's PSMA-PET imaging agents could include approximately 800,000 additional scans in the U.S. [5]